Efficacy of Korteksin in acute period of hemispheric ischemic stroke

Belova L.A.; Mashin V.V.; Abramova V.V.; Slastyon E.Yu.; Belov D.V.

doi:https://doi.org/10.17116/jnevro20181187130

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Mashin V.V.

Abramova V.V.

Slastyon E.Yu.

Ulyanovsk State University, Ulyanovsk, Russia

Belov D.V.

Ulyanovsk State University, Ulyanovsk, Russia

Efficacy of Korteksin in acute period of hemispheric ischemic stroke

Authors:

Belova L.A., Mashin V.V., Abramova V.V., Slastyon E.Yu., Belov D.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7): 30‑34

DOI: 10.17116/jnevro20181187130

Read: 8791 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Belova LA, Mashin VV, Abramova VV, Slastyon EYu, Belov DV. Efficacy of Korteksin in acute period of hemispheric ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7):30‑34. (In Russ.)
https://doi.org/10.17116/jnevro20181187130

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Sequential use of botulinum toxin A and bovhyaluronidase azoximer in the correction of post-stroke spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):80-85

Central nervous system involvement in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):124-129

Adjuvant pharmacological modulation with Cytoflavin in rehabilitation at stages 2—3 in patients with acute cerebral insufficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85

Potential of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

The possibility of using neurotropic therapy in patients with persistent postural-perceptual dizziness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):89-94

Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90

Anesthetic management of endovascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25

Comparison of fluoroscopy and intracardiac echocardiography for control of endovascular closure of patent foramen ovale. Russian Cardiology Bulletin. 2025;(1):64-69

Abstract:

Objective. To study the efficacy and prolonged effect of repeated treatment with low-doses of the neuroprotection drug cortexin (30 mg, (10+10+10, morning, noon, day), daily) in patients in the acute period of hemispheric ischemic stroke. Material and methods. One hundred and twenty-two patients with hemispheric ischemic stroke were studied. Patients of the first group (n=30) received cortexin in a dose of 20 mg (10+10) intramuscularly along with basic therapy, patients of the second group (n=30) received two courses of cortexin in the same dose for 10 days each with a break of 10 days in-between, patients of the third group (n=30) received only basic therapy, patients of the fourth group (n=32) received cortexin in a dose of 30 mg (10+10+10), two courses for 10 days each with a break of 10 days in-between. NIHSS, modified Rankin scale, Barthel index, Rivermead mobility index, MMSE, MOCA-test were used to evaluate the severity of the condition. Results and conclusion. The most complete regression of neurological deficit during the acute period of ischemic stroke was observed in the fourth group of patients (30 mg (10+10+10) of cortexin, two courses) compared to the 1—3 groups.

Keywords:

cortexin

ischemic stroke

treatment of stroke

neuroprotection

Authors:

Belova L.A.

Ul'ianovskiĭ gosudarstvennyĭ universitet

Mashin V.V.

Abramova V.V.

Slastyon E.Yu.

Ulyanovsk State University, Ulyanovsk, Russia

Belov D.V.

Ulyanovsk State University, Ulyanovsk, Russia

Close metadata

References:

Improvement of delivery of health care by the patient with vascular diseases. Under the editorship of Skvortsova V.I. M.: Real Time; 2011. (In Russ.)
Belova LA, Mashin VV, Saprygina LV, Kravchenko MA, Gnedovskaya EV, Oshchepkova EV, Varakin YuYa, Suslina ZA. Struktura of tserebrovaskulyarny pathology in open population of the efficient population of Ulyanovsk. Annals of clinical and experimental neurology. 2014;8(4):4-8. (In Russ.)
Neurology. National leaders. Under the editorship of Gusev E.I., Konovalov A.N., Skvortsova V.I., Gekht A.B. M.: GEOTAR-media; 2009. (In Russ.)
Lindsay P, Furie KL, Davis SM, Dnnan GA, Norrvig D. World stroke organization global stroke services guidelines and action plan. Int J Stroke. 2014;9(suppl A100):4-13. https://doi.org/10.1111/ijs.12371
Reis C, Akyol O, Ho WM, Araujo C, Huang L, Applegate RII, Zhang JH. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. Biomed Res Int. 2017;4863079.
Gulyaeva NV. Interplay between Brain BDNF and Glutamatergic Systems: A Brief State of the Evidence and Association with the Pathogenesis of Depression. Biochemistry. 2017;82(3):301-307.
Ritsner MS. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Netherlands: Springer; 2010. https://doi.org/10.1007/978-90-481-8553-5
Mashin VV, Belova LA, Bakhtogarimov IR, Bergelson TM, Sharafutdinova RR. Multicenter observational program for evaluation of the effectiveness of the drug Recognan (Citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology. The magazine of neurology and psychiatry of S.S. Korsakov. 2017;117(8):39-43. (In Russ.) https://doi.org/10.17116/jnevro20171178139-43
Mashin VV, Belova LA, Chaplanova OI, Khusnullina AF, Manasyan AM. An Open Clinical Trial of Cortexin in Cerebral Ischemia Neuroscience and Behavioral. Physiology. 2016;46(4):390-393. https://doi.org/10.1007/s11055-016-0247-4
Korteksin — five years’ experience of domestic neurology. Under the editorship of Skoromets A.A., Dyakonov M.M. SPb.: Science; 2005. (In Russ.)
Mashin VV, Belova LA, Chaplanova OI, Khusnullina AF, Manasyan AM. Okrytoye clinical trial of the medicine Korteksin at distsirkulyatorny encephalopathy. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2014;114(9):49-52. (In Russ.)
Mashin VV, Belova LA, Proshin AN, Yevstigneyeva AYu, Abramova VV, Vasitsky NR. Cerebrovaskulyarnaya pathology — new opportunities of the low-dosed neuropatronage. Under the editorial office Skoromtsa A.A., Stakhovskoy L.V. SPb.: Science; 2014. (In Russ.)
Belova LA, Mashin VV, Abramova VV, Proshin AN, Ovsyannikova AN. Efektivnost of a korteksin in the sharp and recovery periods of a polusharny ischemic stroke. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2016;116(10):38-42. (In Russ.) https://doi.org/10.17116/jnevro201611610138-42
Belova L, Mashin V, Belova N. Hypertensive Encephalopathy: The Role Of Arteriovenous Interrelations In The Formation Of Its Clinical-Pathogenetic Subtypes. Experimental & Clinical Cardiology. 2014;20(7):892-898.
Alexandrov NA, Evzelman MA. Cerebrovaskulyarnaya of pathology — new opportunities of the low-dosed neuropatronage. Under the editorship of Skoromts A.A., Stakhovskoy L.V. SPb.: Science; 2014. (In Russ.)